[
    [
        {
            "time": "2018-10-24",
            "original_text": "Incyte (INCY) to Report Q3 Earnings: What's in the Cards?",
            "features": {
                "keywords": [
                    "Q3 Earnings",
                    "Incyte"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Incyte (INCY) to Report Q3 Earnings: What's in the Cards?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-25",
            "original_text": "Pfizer Succeeds in Pain Study, Forms JV to Make CNS Drugs",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Pain Study",
                    "JV",
                    "CNS Drugs"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pfizer Succeeds in Pain Study, Forms JV to Make CNS Drugs",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-24",
            "original_text": "Recommendations for Allergan on October 24",
            "features": {
                "keywords": [
                    "Allergan",
                    "Recommendations"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Recommendations for Allergan on October 24",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-10-26",
            "original_text": "New pain drug from Pfizer and Eli Lilly shows promise as opioid alternative",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Eli Lilly",
                    "pain drug",
                    "opioid alternative"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "New pain drug from Pfizer and Eli Lilly shows promise as opioid alternative",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-27",
            "original_text": "Pfizer-Lilly non-opioid drug helps reduce osteoarthritis pain",
            "features": {
                "keywords": [
                    "Pfizer-Lilly",
                    "non-opioid",
                    "osteoarthritis pain"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pfizer-Lilly non-opioid drug helps reduce osteoarthritis pain",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "CMTA Fast Tracks NDA Filing, USNA In Good Health, DERM To Report Data In Apr.",
            "features": {
                "keywords": [
                    "CMTA",
                    "NDA Filing",
                    "USNA",
                    "DERM",
                    "Data"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "CMTA Fast Tracks NDA Filing, USNA In Good Health, DERM To Report Data In Apr.",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]